CHIKUN/KAJURU REP, HON. FIDELIX BAGUDU, ANNOUNCES NEW APPOINTMENTS TO STRENGTHEN INCLUSIVE GOVERNANCE. (PHOTO).

Image
  Chikun/Kajuru Rep, Hon. Fidelix Bagudu, Announces New Appointments To Strengthen Inclusive Governance The Honourable Member representing the Chikun/Kajuru Federal Constituency, Hon. Fidelix Joseph Bagudu, has announced a wide-ranging list of new appointments aimed at deepening inclusive governance and enhancing representation across the constituency. The appointments, which take immediate effect, were unveiled in alignment with Kaduna State Governor Senator Uba Sani’s commitment to participatory governance. According to the lawmaker’s office, the list reflects deliberate efforts to ensure fair representation of all wards, communities, and interest groups across Chikun and Kajuru Local Government Areas (LGAs). A statement issued by the Media and Publicity Directorate noted that the move also fulfills the Honourable Member’s campaign pledge to integrate every segment of the constituency into the decision-making and governance structure. The appointments cover several categories, in...

GSK CEO TO RESIGN BY THE END OF THE YEAR. (PHOTO).


 GSK CEO to resign by the end of the year

GSK Chief Executive Emma Walmsley, the first woman to lead a major pharmaceutical company, will step down on Dec. 31 after more than eight years at the helm of the London-based drugmaker.

Walmsley, 56, will be succeeded by Luke Miels, currently GSK’s chief commercial officer, the company announced Monday. During her tenure, Walmsley oversaw several strategic initiatives, including the spinoff of the consumer health business Haleon, but the company’s overall performance has underwhelmed investors. GSK shares rose 3.3% to 1,534.50 pence in early trading, making it the top gainer on the London Stock Exchange.

Despite these gains, GSK’s stock has fallen 11% since Walmsley took over on April 1, 2017. Analysts say the company has delivered on financial guidance but continues to experience slow growth. Derren Nathan, head of equity research at U.K.-based Hargreaves Lansdown, noted that while GSK has achieved progress, “the share price performance has been lackluster” and growth rates remain in the single digits.

Comments

Popular posts from this blog

SHAKIRA COVERS WOMEN'S HEALTH MAGAZINE,APRIL ISSUE.

INNOSON GIVES OUT BRAND NEW IVM G5 AND SALARY FOR LIFE TO THE MAN WHO PROPHESIED ABOUT HIS VEHICLE MANUFACTURING IN 1979.(PHOTO).

THE NEW OONI OF ILE-IFE,WILL NOT EAT THE HEART OF THE LATE OONI-PALACE CHIEFS.